The results indicated that IGF-1 attenuated the anti-cancer efficiency of zoledronic acid on HeLa cells derived CSCs, strongly suggesting that the effects of zoledronic acid on cervical CSCs are mediated, at least in part, by the Erk1/2 and PI3K/Akt pathways. The gene discussed is MAPK3; the disease is cancer.